DE69637535D1 - Mittel auf basis radiomarkierter peptide zur ortsspezifischen verabreichung - Google Patents

Mittel auf basis radiomarkierter peptide zur ortsspezifischen verabreichung

Info

Publication number
DE69637535D1
DE69637535D1 DE69637535T DE69637535T DE69637535D1 DE 69637535 D1 DE69637535 D1 DE 69637535D1 DE 69637535 T DE69637535 T DE 69637535T DE 69637535 T DE69637535 T DE 69637535T DE 69637535 D1 DE69637535 D1 DE 69637535D1
Authority
DE
Germany
Prior art keywords
somatostatin
peptide
peptides
diagnostic
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69637535T
Other languages
German (de)
English (en)
Inventor
Ananthachari Srinivasan
Mary Marmion Dyszlewski
Joseph E Bugaj
Jack L Erion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Inc
Original Assignee
Mallinckrodt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23907713&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69637535(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mallinckrodt Inc filed Critical Mallinckrodt Inc
Application granted granted Critical
Publication of DE69637535D1 publication Critical patent/DE69637535D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE69637535T 1995-06-07 1996-06-06 Mittel auf basis radiomarkierter peptide zur ortsspezifischen verabreichung Expired - Lifetime DE69637535D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/480,373 US5830431A (en) 1995-06-07 1995-06-07 Radiolabeled peptide compositions for site-specific targeting
PCT/US1996/009384 WO1996040291A1 (en) 1995-06-07 1996-06-06 Radiolabeled peptide compositions for site-specific targeting

Publications (1)

Publication Number Publication Date
DE69637535D1 true DE69637535D1 (de) 2008-07-03

Family

ID=23907713

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69637535T Expired - Lifetime DE69637535D1 (de) 1995-06-07 1996-06-06 Mittel auf basis radiomarkierter peptide zur ortsspezifischen verabreichung

Country Status (10)

Country Link
US (2) US5830431A (es)
EP (2) EP0831938B1 (es)
JP (2) JP4236282B2 (es)
AT (1) ATE395938T1 (es)
CA (1) CA2224153C (es)
DE (1) DE69637535D1 (es)
DK (2) DK0831938T3 (es)
ES (2) ES2308778T3 (es)
PT (1) PT831938E (es)
WO (1) WO1996040291A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849261A (en) * 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US6358491B1 (en) 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
US7067111B1 (en) * 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
JP5448284B2 (ja) * 2000-06-02 2014-03-19 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム エチレンジシステイン（ｅｃ）−薬物結合体
EP1389090A2 (en) * 2001-04-26 2004-02-18 Board of Regents, The University of Texas System Diagnostic imaging compositions, their methods of synthesis and use
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
CN1723042B (zh) * 2002-11-07 2010-12-01 得克萨斯大学体系董事会 乙二半胱氨酸(ec)-药物结合物、组合物及用于组织特异性疾病显像的方法
JP2006522100A (ja) * 2003-03-10 2006-09-28 バイオジェン アイデック インク 標的化ペプチドに対するチオール媒介性薬物結合
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
WO2006094725A1 (en) * 2005-03-10 2006-09-14 Bayer Schering Pharma Aktiengesellschaft Chelators for radioactively labeled conjugates comprising a stabilizing sidechain
US8758723B2 (en) * 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US9345789B2 (en) 2009-12-18 2016-05-24 The Board Of Trustees Of The Leland Stanford Junior University Specific inhibitors and active site probes for legumain
EP2611791A4 (en) 2010-08-12 2014-02-12 Univ New York OLIGOOXOPIPERAZINES AND METHODS FOR THEIR PREPARATION AND USE
EP2814821B1 (en) 2012-02-16 2018-04-25 New York University Control of hypoxia-inducible gene expression with oligooxopiperazine nonpeptidic helix mimetics
CN104768573B (zh) * 2012-05-08 2017-08-29 Trt创新有限责任公司 用于位点特异性uPAR靶向的177‑Lu标记肽
JP2018518526A (ja) 2015-06-25 2018-07-12 アドバンスド アクセレレーター アプリケーションズ ソマトスタチン受容体を過剰発現する神経内分泌腫瘍を処置する方法
AU2018207190B2 (en) 2017-01-12 2020-12-03 Orano Med Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes
US10596278B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
JP2022500464A (ja) 2018-09-11 2022-01-04 サッツ, スタンレイSATZ, Stanley Ｈｅｒ２＋癌および他の新生物の標的放射性核種治療および分子イメージング及び精密治療

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE2512T1 (de) * 1979-11-27 1983-03-15 Sandoz Ag Polypeptide, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen, die diese polypeptide enthalten, und ihre verwendung.
US4282143A (en) * 1980-06-13 1981-08-04 American Home Products Corporation Octapeptides lowering growth hormone
US4440904A (en) * 1983-01-31 1984-04-03 American Home Products Corporation Nonapeptide anti-secretory agents
US4725577A (en) * 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
US4585755A (en) * 1985-04-29 1986-04-29 Merck & Co., Inc. Cyclic and bridged cyclic somatostatin analogs useful as local anti-inflammatory agents
GB9111199D0 (en) * 1991-05-23 1991-07-17 Sandoz Ltd Improvements in or relating to organic compounds
MY106120A (en) * 1988-12-05 1995-03-31 Novartis Ag Peptide derivatives.
US5443816A (en) * 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
JPH04236282A (ja) * 1991-01-18 1992-08-25 Aica Kogyo Co Ltd 接着剤組成物
ES2150916T3 (es) * 1991-08-29 2000-12-16 Mallinckrodt Medical Inc Utilizacion del acido gentisico o del alcohol gentisilico para estabilizar peptidos y proteinas radiomarcados.
US5225180A (en) * 1991-09-10 1993-07-06 Diatech, Inc. Technetium-99m labeled somatostatin-derived peptides for imaging
US5411943A (en) * 1992-02-25 1995-05-02 Biomeasure, Inc. Hepatoma treatment with somatostatin analogs
SK2094A3 (en) * 1993-01-12 1995-01-12 Sandoz Ag Somatostatine polypeptides, method of their preparing and using
US5650134A (en) * 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
ES2229045T3 (es) * 1993-08-09 2005-04-16 Sod Conseils Rech Applic Derivados de peptidos terapeuticos.
CA2175557A1 (en) * 1993-11-16 1995-05-26 Alfred Pollak Immobilized labelling method
WO1995019187A1 (en) * 1994-01-12 1995-07-20 Amersham International Plc Biological targeting agents
EP0835662B1 (en) * 1996-10-08 2001-11-14 National Institute of Immunology A drug for the treatment of cancer

Also Published As

Publication number Publication date
EP0831938A1 (en) 1998-04-01
WO1996040291A1 (en) 1996-12-19
JP2008266342A (ja) 2008-11-06
JP4236282B2 (ja) 2009-03-11
EP0831938B1 (en) 2008-05-21
ES2395961T3 (es) 2013-02-18
US5830431A (en) 1998-11-03
ES2308778T3 (es) 2008-12-01
ATE395938T1 (de) 2008-06-15
CA2224153C (en) 2010-08-17
PT831938E (pt) 2008-08-26
EP1872800A2 (en) 2008-01-02
EP0831938A4 (en) 2001-12-05
US5804157A (en) 1998-09-08
DK0831938T3 (da) 2008-07-21
JPH11507342A (ja) 1999-06-29
CA2224153A1 (en) 1996-12-19
DK1872800T3 (da) 2013-02-04
EP1872800B1 (en) 2012-10-17
EP1872800A3 (en) 2008-03-19

Similar Documents

Publication Publication Date Title
DE69637535D1 (de) Mittel auf basis radiomarkierter peptide zur ortsspezifischen verabreichung
WO1998018497A3 (en) Contrast agents
WO2003028527A3 (en) Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
WO1998018496A3 (en) Contrast agents
AU3368497A (en) Human dnase i hyperactive variants
DE59007517D1 (de) Neue proteine mit tnf-hemmender wirkung und ihre herstellung.
DE69735580D1 (de) An aminosaeure angereicherte speicherproteine, insbesondere an lysin angereicherte mais-gamma-zeine, und diese exprimierende pflanzen
FR2846883B1 (fr) Composition cosmetique comprenant, comme ingredient actif, au moins un peptide et utilisation de ce peptide
NZ234173A (en) Alpha-melanocyte stimulating hormone derivative (alphamsh)-targetted moiety conjugate
ATE203665T1 (de) Stabilisierte pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung
EP1279677A4 (en) GD3 MIMETIC PEPTIDES
PT1095143E (pt) Inibidor para o diagnóstico e tratamento de doentes com hemofilia a
EE200000478A (et) Peptiid, seda kodeeriv geen, diagnostiline reagent ja diagnostiline reaktiivikomplekt ning vaktsiinkasutamiseks riketsioosi ravis
ZA961419B (en) Human DNase I variants.
TR199700842T1 (xx) �nsan DNase I Varyantlar�.
DE69730967D1 (en) Human dnase ii
EP0858808A3 (en) Peptides for use in wound treatment
BG101847A (en) Human dnase i variants

Legal Events

Date Code Title Description
8364 No opposition during term of opposition